## Glanbia plc Transaction in Own Shares

Monday, February 10, 2025 Glanbia plc ("Glanbia" or the "Company"), the Better Nutrition company, announces that on Friday, February 7, 2025 it purchased the following number of its ordinary shares (the "Ordinary Shares") on Euronext Dublin, via Glanbia's broker J&E Davy. The Ordinary Shares purchased will be cancelled.

	Euronext Dublin
Number of Ordinary Shares purchased:	40,000
Highest price paid per Ordinary Share:	€14.3000
Lowest price paid per Ordinary Share:	€14.2000
Volume weighted average price paid per Ordinary Share:	€14.2206

The Ordinary Shares purchased form part of Glanbia's intention to buy back the Company's Ordinary Shares of a total value of up to €50 million in the period up to 30 June 2025 ("**Buy-Back Programme**"). This Buy-Back Programme was announced on 6 November 2024 and formally commenced on 16 December 2024.

Following settlement of the above transactions and subsequent share cancellation Glanbia will hold 257,823,489 ordinary shares in issue.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a detailed breakdown of individual trades made by Davy on behalf of Glanbia as part of the buyback programme is scheduled to this announcement.

Contact: Liam Hennigan Group Secretary and Head of Investor Relations Tel: + 353 86 046 8375

Olivia Kennington Deputy Group Secretary Tel: + 35356 777 2200

Issuer name:	Glanbia plc	
LEI	635400SRMCBHVMSKJS84	
ISIN:	IE0000669501	
Intermediary name:	J&E Davy	
Intermediary code:	DAVYIE21	
Time zone:	GMT	
Currency:	EUR	

## Aggregated Information

Trading venue	Currency	Volume Weighted Average Price	Aggregated volume
Euronext Dublin	EUR	14.2206	40,000

## **Euronext Dublin**

Number of Shares	Price per Share (EUR)	Trading Venue	Time of Transaction	Matchld
2255	14.3	Euronext Dublin	10:33:33	00043801916TRLO0-1
20000	14.23	Euronext Dublin	10:59:04	00043802371TRLO0-1
17745	14.2	Euronext Dublin	14:33:01	00043806060TRLO0-1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

POSBIGDDBBGDGUR